165 CSL Limited Annual Report 2025/26 Key Performance Data Summary Reporting boundary CSL’s key performance data summary covers operations over which CSL Limited exercises direct control, including CSL Behring (including CSL Plasma), CSL Seqirus, CSL Vifor and R&D. This encompasses CSL’s nine manufacturing facilities across Australia, Europe, the UK and the United States, as well as R&D, sales and marketing, distribution and administrative activities co-located with these sites. The reporting boundary also extends to activities performed outside manufacturing facilities, including R&D, sales and marketing, distribution and administrative functions, as well as the full network of donation centres, laboratories and administrative offices operated by CSL Plasma. Performance indicator Measure 23/24 24/25 25/26 More in 25/26 Annual Report (page reference) Operating revenue US$ million 14,800¶^ 15,558¶^ 15,797¶^ 88 Net profit/(loss) after tax US$ million 2,642¶^ 3,002¶^ (2,579)¶^ 88 Economic value generated* US$ million 14,839#^ 15,596#^ 15,828#^ Economic value distributed* US$ million 13,516#^ 14,066#^ 14,958#^ 26 CSL’s people Total workforce Number 32,698#^ 29,904#^ 28,933#^ CGS 14 Total Board female Percentage 56#^ 60#^ 40#^ CGS 14 Total workforce female Percentage 59#^ 56.5#^ 57.4#^ CGS 14 Total people managers female Percentage 46#^ 45.9#^ 45.4#^ CGS 14 Total senior executives female Percentage 34#^ 36.3#^ 39.7#^ CGS 14 Total Recordable Injury Frequency Rate (TRIFR) Per million hours worked for Non‑CSL Plasma sites 0.70#^ 0.62#^ 0.68#^ 39 Per million hours worked for CSL Plasma 9.75#^ 6.90#^ 2.56#^ 39 Fatalities (employees and contingent workers) Number 0#^ 0#^ 0#^ 39 Employee engagement Percentage 74.8#^ 72.9#^ 67.2#^ 6 ESG employee engagement** Percentage 75.1#^ 75.9#^ 73.9#^ Healthier Communities Innovation R&D investment US$ million 1,428¶^ 1,359¶^ 1,223¶^ 109 Clinical trials in operation Number 60 59 41 16 Safety and quality Regulatory inspections of manufacturing facilities and plasma collection centres Number 479#^ 403#^ 381#^ 38 Safety-related recalls of finished product†† Number 2#^ 2#^ 4#^ 38 Community Product access support (subset of total community contribution)*** US$ million 15.7# 16.5# 22.3# 26 Plasma donors willing to donate again Percentage 94# 93# 88# **** 30 Plasma donors willing to refer a friend Percentage 90# 90# 63# **** CGS = Corporate Governance Statement, which can be accessed at https://www.csl.com/we-are-csl/corporate-governance.
RkJQdWJsaXNoZXIy MjE2NDg3